JP2019527204A - 抑制性免疫受容体阻害方法および組成物 - Google Patents

抑制性免疫受容体阻害方法および組成物 Download PDF

Info

Publication number
JP2019527204A
JP2019527204A JP2018567892A JP2018567892A JP2019527204A JP 2019527204 A JP2019527204 A JP 2019527204A JP 2018567892 A JP2018567892 A JP 2018567892A JP 2018567892 A JP2018567892 A JP 2018567892A JP 2019527204 A JP2019527204 A JP 2019527204A
Authority
JP
Japan
Prior art keywords
antibody
inhibitory
inhibitor
individual
siglec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018567892A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527204A5 (enExample
Inventor
エリオット シー． ウッズ、
エリオット シー． ウッズ、
ハン シャオ、
ハン シャオ、
キャロライン アール． ベルトッツィ、
キャロライン アール． ベルトッツィ、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2019527204A publication Critical patent/JP2019527204A/ja
Publication of JP2019527204A5 publication Critical patent/JP2019527204A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018567892A 2016-07-01 2017-06-30 抑制性免疫受容体阻害方法および組成物 Pending JP2019527204A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662357653P 2016-07-01 2016-07-01
US62/357,653 2016-07-01
PCT/US2017/040483 WO2018006066A1 (en) 2016-07-01 2017-06-30 Inhibitory immune receptor inhibition methods and compositions

Publications (2)

Publication Number Publication Date
JP2019527204A true JP2019527204A (ja) 2019-09-26
JP2019527204A5 JP2019527204A5 (enExample) 2020-08-06

Family

ID=60787693

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018567892A Pending JP2019527204A (ja) 2016-07-01 2017-06-30 抑制性免疫受容体阻害方法および組成物

Country Status (7)

Country Link
US (2) US20190300606A1 (enExample)
EP (1) EP3478315A4 (enExample)
JP (1) JP2019527204A (enExample)
CN (1) CN109414490A (enExample)
AU (1) AU2017290884A1 (enExample)
CA (1) CA3026588A1 (enExample)
WO (1) WO2018006066A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7060502B2 (ja) 2015-10-29 2022-04-26 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－９抗体及びその使用方法
MX2019013648A (es) 2017-05-19 2021-01-08 Wuxi Biologics Shanghai Co Ltd Anticuerpos monoclonales novedosos para proteina 4 asociada con el linfocito t citotoxico (ctla-4).
MX2020007024A (es) 2018-01-03 2020-10-28 Palleon Pharmaceuticals Inc Sialidasas humanas recombinantes, proteinas de fusion de sialidasa y metodos para usar las mismas.
WO2019200462A1 (en) * 2018-04-16 2019-10-24 Adaerata, Limited Partnership Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers
BR112021012631A2 (pt) 2018-12-26 2021-12-14 Xilio Dev Inc Anticorpos anti-ctla4 e métodos de uso dos mesmos
AU2020301037A1 (en) * 2019-07-03 2022-02-03 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
WO2021003465A1 (en) * 2019-07-03 2021-01-07 Palleon Pharmaceuticals Inc. Sialidase-her2-antibody fusion proteins and methods of use thereof
CN114667298A (zh) 2019-11-04 2022-06-24 艾利妥 Siglec-9 ecd融合分子及其使用方法
US20230210841A1 (en) * 2020-05-15 2023-07-06 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Compounds for inhibiting ly6k and methods of using same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528626A (ja) * 2003-07-24 2006-12-21 イナート・ファルマ・ソシエテ・アノニム Ｎｋ細胞増強化合物を使用する治療抗体の有効性を増大させる方法および組成物
JP2011518824A (ja) * 2008-04-23 2011-06-30 シュティヒティング サンクイン ブロエドフォールツィーニング 免疫系を増強する為の組成物および方法
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10081681B2 (en) * 2013-09-20 2018-09-25 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
US20170158776A1 (en) * 2014-05-15 2017-06-08 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
WO2016025647A1 (en) * 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
BR112017003582B1 (pt) * 2014-08-27 2024-01-09 Memorial Sloan Kettering Cancer Center Agente de anticorpo, uso do mesmo, composição farmacêutica e receptor de antígeno quimérico
WO2016038064A1 (en) * 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies
RU2017119428A (ru) * 2014-11-06 2018-12-06 Дженентек, Инк. Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528626A (ja) * 2003-07-24 2006-12-21 イナート・ファルマ・ソシエテ・アノニム Ｎｋ細胞増強化合物を使用する治療抗体の有効性を増大させる方法および組成物
JP2011518824A (ja) * 2008-04-23 2011-06-30 シュティヒティング サンクイン ブロエドフォールツィーニング 免疫系を増強する為の組成物および方法
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL PHARMACOLOGY, vol. 82, JPN6021029814, 2011, pages 323 - 332, ISSN: 0004778755 *
NAT CHEM BIOL, vol. 10, no. 1, JPN6021029813, 2014, pages 69 - 75, ISSN: 0004778756 *

Also Published As

Publication number Publication date
US20190300606A1 (en) 2019-10-03
CN109414490A (zh) 2019-03-01
US20220169724A1 (en) 2022-06-02
WO2018006066A1 (en) 2018-01-04
EP3478315A1 (en) 2019-05-08
CA3026588A1 (en) 2018-01-04
AU2017290884A1 (en) 2019-01-31
EP3478315A4 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
JP2019527204A (ja) 抑制性免疫受容体阻害方法および組成物
US20230159640A1 (en) Carrier-pd-l1 binding agent compositions for treating cancers
US10487150B2 (en) SIRP alpha-antibody fusion proteins
JP2018508483A (ja) 抗ｌａｐモノクローナル抗体による癌の処置
JP2024016220A (ja) 抗体－薬物コンジュゲートを用いた免疫応答の調節
KR20190125398A (ko) 글리칸-상호작용 화합물 및 사용 방법
TW202506732A (zh) 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
US20240374644A1 (en) Herv-k antibody therapeutics
TW202311293A (zh) 免疫療法之組合及其用途
WO2024219442A1 (ja) 抗体－薬物コンジュゲートと他の薬剤との組み合わせ
JP2025517656A (ja) 腫瘍抗原に特異的である抗体と、ｃｄ４７阻害剤との組合せ
US12129305B2 (en) Targeting CLPTM1L for treatment and prevention of cancer
JP2023525053A (ja) 皮膚ｔ細胞リンパ腫及びｔｆｈ由来リンパ腫を処置する新しい方法
KR20220146488A (ko) 항-cd30 항체-약물 컨쥬게이트 및 비-호지킨 림프종의 치료를 위한 그의 용도
WO2024146539A1 (en) Bispecific antibodies against pd-l1 and cd47, method for preparing the same, and use thereof
US20220242966A1 (en) Cd63 agonist-related methods and compositions
WO2025226603A1 (en) Methods for treating cancer using anti-ccr8 antibodies
KR20250160353A (ko) 항-ceacam5 항체-약물 접합체, 항-vegfr-2 항체 및 항-pd1/pd-l1 항체를 함유하는 항종양 조합물
WO2024236156A1 (en) Anti-cathepsin-d antibodies
KR20250175330A (ko) 항체-약물 콘주게이트와 다른 약제의 조합
US20230390424A1 (en) Trophoblast glycoprotein radioimmunotherapy for the treatment of solid cancers
WO2022097047A1 (en) Treatment methods using anti-bcma antibody-drug conjugates
HK40052936B (zh) 使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合治疗癌症的方法
HK40042823A (en) Anti-cd73 antibodies and methods of use thereof
HK40052936A (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220524